Aura Biosciences Inc.

Plus: Oppenheimer promotes Margolis; Biofidelity and Annexon each announce trio of hires; and Aura gets a new SVP

Dozens of companies aim to avoid immunogenicity and improve tissue-specificity

Eight biopharmas brought in a combined $949M in follow-on financing; nearly all had gained value by the end of the month

Plus: Restructuring at Kezar as CEO, CMO step down, and updates from Atomwise, Aura, Twist, Acelyrin and more

Sixteen biopharmas raised $1.5B in follow-ons in November

BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference

Ahead of first Phase III readout, Vifor acquires cardio-renal therapy developer Sanifit for €205M up front

Plus FDA approves Novartis’ first-in-class STAMP inhibitor for CML and IPOs from Entrada, Aura and more

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) promoted Bart Filius to president from CFO while remaining COO. CEO Onno van de Stolpe will be responsible for oversight of R&D activities. Caroline

An $80 million crossover series E round will support 12-year-old Aura’s first pivotal trial based on its virus-like particle conjugation technology: a Phase III study in choroidal melanoma, an